| |  Online-Ressource |
|---|
| Verfasst von: | Emre, Murat [VerfasserIn]  |
|---|
| | Bernabei, Roberto [VerfasserIn] |
|---|
| | Blesa, Rafael [VerfasserIn] |
|---|
| | Bullock, Roger [VerfasserIn] |
|---|
| | Cunha, Luis [VerfasserIn] |
|---|
| | Daniëls, Hugo [VerfasserIn] |
|---|
| | Dziadulewicz, Edward [VerfasserIn] |
|---|
| | Förstl, Hans [VerfasserIn] |
|---|
| | Frölich, Lutz [VerfasserIn] |
|---|
| | Gabryelewicz, Tomasz [VerfasserIn] |
|---|
| | Levin, Oleg [VerfasserIn] |
|---|
| | Lindesay, James [VerfasserIn] |
|---|
| | Martínez-Lage, Pablo [VerfasserIn] |
|---|
| | Monsch, Andreas [VerfasserIn] |
|---|
| | Tsolaki, Magda [VerfasserIn] |
|---|
| | Van Laar, Teus [VerfasserIn] |
|---|
| Titel: | Drug profile |
|---|
| Titelzusatz: | transdermal rivastigmine patch in the treatment of Alzheimer disease |
|---|
| Verf.angabe: | Murat Emre, Roberto Bernabei, Rafael Blesa, Roger Bullock, Luis Cunha, Hugo Daniëls, Edward Dziadulewicz, Hans Förstl, Lutz Frölich, Tomasz Gabryelewicz, Oleg Levin, James Lindesay, Pablo Martínez-Lage, Andreas Monsch, Magda Tsolaki & Teus Van Laar |
|---|
| E-Jahr: | 2010 |
|---|
| Jahr: | 1 July 2010 |
|---|
| Umfang: | 8 S. |
|---|
| Fussnoten: | Gesehen am 22.05.2023 |
|---|
| Titel Quelle: | Enthalten in: CNS neuroscience & therapeutics |
|---|
| Ort Quelle: | Oxford : Wiley-Blackwell, 2008 |
|---|
| Jahr Quelle: | 2010 |
|---|
| Band/Heft Quelle: | 16(2010), 4 vom: Aug., Seite 246-253 |
|---|
| ISSN Quelle: | 1755-5949 |
|---|
| Abstract: | Cholinesterase inhibitors constitute one of the mainstays of treatment of Alzheimer disease (AD). Gastrointestinal side effects, difficulty accessing therapeutic doses and poor patient compliance have been identified as barriers to effective treatment with these substances. The rivastigmine transdermal patch provides continuous delivery of drug through the skin into the bloodstream, avoiding the fluctuations in plasma concentration associated with oral administration. This pharmacokinetic profile is associated with reduced side effects, resulting in easier access to expected target doses. These benefits, along with other practical advantages of the transdermal patch, may contribute to enhanced patient compliance. Here, we present a review of the current literature on rivastigmine patch, and offer advice based on our own collective clinical experience. Rivastigmine patch provides an efficient option for managing patients with AD, to be considered among the first line therapies for the disease. |
|---|
| DOI: | doi:10.1111/j.1755-5949.2010.00141.x |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1111/j.1755-5949.2010.00141.x |
|---|
| | Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1755-5949.2010.00141.x |
|---|
| | DOI: https://doi.org/10.1111/j.1755-5949.2010.00141.x |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Alzheimer's disease |
|---|
| | Patch |
|---|
| | Rivastigmine |
|---|
| | Transdermal |
|---|
| | Treatment |
|---|
| K10plus-PPN: | 1845905997 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
